BISPHOSPHONATES – A GOOD CHOICE FOR WOMEN WITH TYPE
2 DIABETES AND POSTMENOPAUSAL OSTEOPOROSIS?
RALUCA NAN1, DANIEL GRIGORIE2,3*, ADRIAN CURSARU4, ALINA ȘUCALIUC2,3, RAMONA DRĂGUȚ1, EMILIA RUSU1, MĂDĂLINA MUȘAT2,3, GABRIELA RADULIAN 1,5
1Department of Diabetes 2, ”Prof. Dr. N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, 5-7
Ion Movilă Street, Bucharest, Romania
2”C. I. Parhon” National Institute of Endocrinology, 34-36 Aviatorilor Boulevard, Bucharest, Romania
3Department of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, 34-36 Aviatorilor Boulevard,
Bucharest, Romania
4Department of Orthopaedics and Traumatology, “Carol Davila” University of Medicine and Pharmacy, 169 Splaiul
Independenței, Bucharest, Romania
5Department of Hygiene and Diabetes, “Carol Davila” University of Medicine and Pharmacy, 17-23 Calea Plevnei,
Bucharest, Romania
*corresponding author: grigorie_d@yahoo.com
Download Full Article

Abstract:
The aim of the study was to assess the levels of biochemical markers of bone turnover (BTMs) and the effects of
bisphosphonates therapy (BT) on BTMs and bone mineral density (BMD) in women with type 2 diabetes (T2D) and recently
diagnosed postmenopausal osteoporosis. Two groups of women have been evaluated at baseline and one year later: a group
of 35 women diagnosed with T2D and newly postmenopausal osteoporosis (diabetic group) and a group of 35 women only
with postmenopausal osteoporosis (control group). Consistent with other studies, we found that bone turnover was reduced in
T2D patients, as both serum osteocalcin and C-terminal crosslink of collagen (CTX) were significantly lower than controls.
After a year of BT, both osteocalcin and CTX did not change in the diabetic group and decreased in the control group.
Significant increases in BMD, especially at the lumbar spine, were noted in both groups. In diabetic women, bone turnover is
low and does not change after one year of BT, but there is a significant benefit at lumbar spine BMD.

Top